Focus on HIV Care

Back to articles

Coming soon: Abacavir hypersensitivity screening?

KEY POINT

An experimental genetic test for HLA-B*5701 may distinguish patients who are predisposed to developing a hypersensitivity reaction to abacavir (Ziagen—GlaxoSmithKline). Currently, use of this test is limited by expense, availability, and a prolonged turnaround time. New methodologies are being developed to overcome these barriers.

SOURCES

Rauch A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reaction in the Western Australian HIV cohort study. Clin Infect Dis. 2006;43:99–102.

Phillips EJ. Genetic screening to prevent hypersensitivity reaction: are we there yet [editorial]? Clin Infect Dis. 2006;43:103–5.

Chui C et al. A simple screening approach to reduce abacavir hypersensitivity reactions. Interscience Conference on Antimicrobial Agents and Chemotherapy 2006; H-1905a.[abstract].

FDA Web site.

James JS. Genetic testing may avoid abacavir hypersensitivity reaction. AIDS Treatment News.